<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event
reported): June 19, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Apricus Biosciences, Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">(Exact name of registrant as specified in its charter)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Nevada</TD>
    <TD STYLE="width: 34%; font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">0-22245</TD>
    <TD STYLE="width: 33%; font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">87-0449967</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation)</P></TD>
    <TD STYLE="font-size: 10pt; text-align: center">(Commission File Number)</TD>
    <TD STYLE="font-size: 10pt; text-align: center">(I.R.S. Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 61%; font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">11975 El Camino Real, Suite 300, San Diego, CA</TD>
    <TD NOWRAP STYLE="width: 39%; font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">92130</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">(Address of principal executive offices)</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code&nbsp;(858) 222-8041</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed,
since last report.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings 2">&pound;</FONT></TD><TD>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings 2">&pound;</FONT></TD><TD>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings 2">&pound;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings 2">&pound;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 1.2in; text-align: left"><B>Item&nbsp;1.01.</B></TD><TD STYLE="text-align: justify"><B>Entry into a Material Definitive Agreement.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 19, 2012, Apricus Biosciences,
Inc. (the &ldquo;<B><I>Company</I></B>&rdquo;) entered into a Stock Contribution Agreement (the &ldquo;<B><I>Contribution Agreement</I></B>&rdquo;)
by and among the Company, Finesco, a holding company incorporated in France (&ldquo;<B><I>Finesco</I></B>&rdquo;), Scomedica, a
company incorporated in France and the wholly owned subsidiary of Finesco (&ldquo;<B><I>Scomedica</I></B>&rdquo;) (collectively,
Finesco and Scomedica shall be hereinafter referred to as the &ldquo;<B><I>Target Companies</I></B>&rdquo;) and the shareholders
of Finesco named therein (the &ldquo;<B><I>Shareholders</I></B>&rdquo;). Pursuant to the Contribution Agreement, the Shareholders
will contribute all of the outstanding capital stock of Finesco to the Company in exchange for a number of shares of the Company&rsquo;s
common stock calculated as follows: (i) shares valued at &euro;7,000,000 deliverable at closing (the &ldquo;<B><I>Initial Contribution
Amount</I></B>&rdquo;) and (ii) additional shares valued at &euro;1,818,088 deliverable only if Net Revenue (as defined in the
Contribution Agreement) for Scomedica for the twelve months ended December 31, 2012 equals or exceeds &euro;8,000,000 (the &ldquo;<B><I>Additional
Contribution Amount</I></B>&rdquo;). The Additional Contribution Amount shares will be issuable, if at all, on or before the fifth
(5th) Business Day after the issuance by Scomedica&rsquo;s statutory auditor of its general report on its financial statements
for the fiscal year ended December 31, 2012 (the &ldquo;<B><I>Additional Contribution Payment Deadline</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares deliverable as the Initial Contribution
Amount and Additional Contribution Amount will be valued at the volume-weighted average price of Company&rsquo;s common stock on
the NASDAQ Capital Market for the ten (10) trading days immediately preceding (i) the date of closing for the Initial Contribution
Amount or (ii) the Additional Contribution Payment Deadline, as applicable. Any portion of the shares deliverable pursuant to the
Contribution Agreement that cause the number of shares issued to the Shareholders to exceed 19.99% of the total outstanding shares
of the Company shall be paid in cash in lieu of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Shareholders have agreed to have fifteen
percent (15%) of the shares issued at the closing delivered to an escrow agent, and held by such agent for a period of one year
from the closing date to secure the Shareholder&rsquo;s indemnification obligations in respect of any breaches of the representations,
warranties and covenants of the Shareholders and Target Companies. The Contribution Agreement also provides for a post-closing
working capital adjustment if the actual working capital as of the closing date, calculated as of a date within 45 days after the
closing date, deviates from the target working capital set forth in the Contribution Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a condition to closing, the Company
and Sellers have agreed to enter into a Registration Rights and Transfer Restriction Agreement, pursuant to which, among other
things, the Shareholders would be restricted from selling on any given day more than five percent (5%) of the prior day&rsquo;s
total share trading volume as reported on the NASDAQ Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain of the Shareholders (each a &ldquo;<B><I>Restricted
Person</I></B>&rdquo;) have agreed to not compete directly or indirectly with the business of the Target Companies for a period
of three years with respect to certain Shareholders and one year with respect to another Shareholder, including prohibitions from;
(i) engaging in or assisting others in engaging in the Restricted Business (as defined in the Contribution Agreement) in France;
(ii) having any financial or equity interest in any entity that engages directly or indirectly in the Restricted Business in France
in any capacity, including as a partner, shareholder, member, employee, principal, agent, trustee or consultant (other than interests
in the Company or any successor); or (iii) intentionally interfering in any material respect with the business relationships between
the Target Companies and customers or suppliers of the Company and Target Companies. Notwithstanding the foregoing, a Restricted
Person may own, directly or indirectly, solely as an investment, securities of any entity traded on any national securities exchange
if the Restricted Person does not directly or indirectly own 5% or more of any class of securities of such entity. Further, the
Restricted Persons are prohibited from soliciting for employment any employee of the Company or Target Companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, Target Companies and Shareholders
have agreed to additional covenants and closing conditions, including covenants on the part of the Target Companies to continue
to operate in the ordinary course, to allow the Company access to information, to not solicit other bids, to provide notice of
certain events and other customary covenants. The conditions to closing include execution of executive employment agreements with
certain key executives, receipt of all necessary approvals, resignations of directors and officers of the Target Companies, the
execution of the Registration Rights and Transfer Restriction Agreement and the Escrow Agreement and other customary conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This
report does not constitute an offer to sell or solicitation of an offer to buy any securities. The shares to be contributed by
the Company have not been registered under the Securities Act of 1933, as amended, and are to be issued, subject to the satisfaction
or waiver of the conditions to issuance, pursuant to exemptions from the registration provisions of such Act. The shares may not
be re-offered or resold in the United States absent registration or an applicable exemption from registration requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">Apricus Biosciences, Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 55%">&nbsp;Date: June 20, 2012</TD>
    <TD STYLE="width: 3%">By:&nbsp;</TD>
    <TD STYLE="width: 27%; border-bottom: Black 1pt solid">&nbsp; /s/ Randy Berholtz</TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name: Randy Berholtz</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Title: Executive Vice President, General Counsel and Secretary</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v316482_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 18943}]
{"company-data": {"conformed-name": "APRICUS BIOSCIENCES, INC.", "cik": "0001017491", "assigned-sic": "2834", "irs-number": "870449967", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-22245", "film-number": "12917424"}, "business-address": {"street1": "6330 NANCY RIDGE DRIVE,", "street2": "SUITE 103", "city": "SAN DIEGO,", "state": "CA", "zip": "92121", "phone": "(858) 222-8041"}, "mail-address": {"street1": "6330 NANCY RIDGE DRIVE,", "street2": "SUITE 103", "city": "SAN DIEGO,", "state": "CA", "zip": "92121"}, "former-company": {"former-conformed-name": "NEXMED INC", "date-changed": "19970311"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): June 19, 2012
Apricus Biosciences, Inc.
(Exact name of registrant as specified in its charter)
Nevada
0-22245
87-0449967
(State or other jurisdiction of
incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
11975 El Camino Real, Suite 300, San Diego, CA
92130
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including
area code (858) 222-8041
(Former name or former address, if changed,
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
£
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
£
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
£
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
£
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))
Item 1.01.
Entry into a Material Definitive Agreement.
On June 19, 2012, Apricus Biosciences,
Inc. (the "
Company
") entered into a Stock Contribution Agreement (the "
Contribution Agreement
")
by and among the Company, Finesco, a holding company incorporated in France ("
Finesco
"), Scomedica, a
company incorporated in France and the wholly owned subsidiary of Finesco ("
Scomedica
") (collectively,
Finesco and Scomedica shall be hereinafter referred to as the "
Target Companies
") and the shareholders
of Finesco named therein (the "
Shareholders
"). Pursuant to the Contribution Agreement, the Shareholders
will contribute all of the outstanding capital stock of Finesco to the Company in exchange for a number of shares of the Company's
common stock calculated as follows: (i) shares valued at €7,000,000 deliverable at closing (the "
Initial Contribution
Amount
") and (ii) additional shares valued at €1,818,088 deliverable only if Net Revenue (as defined in the
Contribution Agreement) for Scomedica for the twelve months ended December 31, 2012 equals or exceeds €8,000,000 (the "
Additional
Contribution Amount
"). The Additional Contribution Amount shares will be issuable, if at all, on or before the fifth
(5th) Business Day after the issuance by Scomedica's statutory auditor of its general report on its financial statements
for the fiscal year ended December 31, 2012 (the "
Additional Contribution Payment Deadline
").
The shares deliverable as the Initial Contribution
Amount and Additional Contribution Amount will be valued at the volume-weighted average price of Company's common stock on
the NASDAQ Capital Market for the ten (10) trading days immediately preceding (i) the date of closing for the Initial Contribution
Amount or (ii) the Additional Contribution Payment Deadline, as applicable. Any portion of the shares deliverable pursuant to the
Contribution Agreement that cause the number of shares issued to the Shareholders to exceed 19.99% of the total outstanding shares
of the Company shall be paid in cash in lieu of shares.
The Shareholders have agreed to have fifteen
percent (15%) of the shares issued at the closing delivered to an escrow agent, and held by such agent for a period of one year
from the closing date to secure the Shareholder's indemnification obligations in respect of any breaches of the representations,
warranties and covenants of the Shareholders and Target Companies. The Contribution Agreement also provides for a post-closing
working capital adjustment if the actual working capital as of the closing date, calculated as of a date within 45 days after the
closing date, deviates from the target working capital set forth in the Contribution Agreement.
As a condition to closing, the Company
and Sellers have agreed to enter into a Registration Rights and Transfer Restriction Agreement, pursuant to which, among other
things, the Shareholders would be restricted from selling on any given day more than five percent (5%) of the prior day's
total share trading volume as reported on the NASDAQ Capital Market.
Certain of the Shareholders (each a "
Restricted
Person
") have agreed to not compete directly or indirectly with the business of the Target Companies for a period
of three years with respect to certain Shareholders and one year with respect to another Shareholder, including prohibitions from;
(i) engaging in or assisting others in engaging in the Restricted Business (as defined in the Contribution Agreement) in France;
(ii) having any financial or equity interest in any entity that engages directly or indirectly in the Restricted Business in France
in any capacity, including as a partner, shareholder, member, employee, principal, agent, trustee or consultant (other than interests
in the Company or any successor); or (iii) intentionally interfering in any material respect with the business relationships between
the Target Companies and customers or suppliers of the Company and Target Companies. Notwithstanding the foregoing, a Restricted
Person may own, directly or indirectly, solely as an investment, securities of any entity traded on any national securities exchange
if the Restricted Person does not directly or indirectly own 5% or more of any class of securities of such entity. Further, the
Restricted Persons are prohibited from soliciting for employment any employee of the Company or Target Companies.
The Company, Target Companies and Shareholders
have agreed to additional covenants and closing conditions, including covenants on the part of the Target Companies to continue
to operate in the ordinary course, to allow the Company access to information, to not solicit other bids, to provide notice of
certain events and other customary covenants. The conditions to closing include execution of executive employment agreements with
certain key executives, receipt of all necessary approvals, resignations of directors and officers of the Target Companies, the
execution of the Registration Rights and Transfer Restriction Agreement and the Escrow Agreement and other customary conditions.
2
This
report does not constitute an offer to sell or solicitation of an offer to buy any securities. The shares to be contributed by
the Company have not been registered under the Securities Act of 1933, as amended, and are to be issued, subject to the satisfaction
or waiver of the conditions to issuance, pursuant to exemptions from the registration provisions of such Act. The shares may not
be re-offered or resold in the United States absent registration or an applicable exemption from registration requirements.
*              *	           *
3
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Apricus Biosciences, Inc.
Date: June 20, 2012
By:
/s/ Randy Berholtz
Name: Randy Berholtz
Title: Executive Vice President, General Counsel and Secretary
4